Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2015-10-20Clinical Trial Update: Drug-Drug Interaction of Cladribine and Pantoprazole in Multiple Sclerosis Subjects [Phase 1]
Phase 1 study evaluating the drug-drug interaction between cladribine and pantoprazole in multiple sclerosis subjects has completed. Results…
-
CLINICAL_TRIALS trial_result · 2015-10-20Clinical Trial Update: Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL Study
A completed clinical trial assessing quality of life and convenience of Avonex in Belgian participants with Multiple Sclerosis.
-
FDA approval · 2015-10-16FDA Approved: TECFIDERA — Supplemental Application (Biogen Inc.)
FDA approves Biogen's supplemental application for Tecfidera (dimethyl fumarate). The action updates the drug's labeling to reflect the supp…
-
CLINICAL_TRIALS trial_result · 2015-10-12Clinical Trial Update: The Effect of Levetiracetam (Keppra) on the Treatment of Tremor in Multiple Sclerosis
A completed clinical trial evaluated whether levetiracetam (Keppra) reduces tremor in patients with multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2015-10-09Clinical Trial Update: Open, Multicentric, Prospective, Quality of Life Study in Multiple Sclerosis Patients
A completed open-label, multicenter prospective trial assessing quality of life in patients with multiple sclerosis sponsored by Bayer.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2015-10-02FDA Approved: COPAXONE — Supplemental Application (Teva Neuroscience, Inc.)
FDA approved a supplemental application for COPAXONE (glatiramer acetate) from Teva Neuroscience, Inc.
-
CLINICAL_TRIALS trial_result · 2015-10-02Clinical Trial Update: Botulinum Toxin Type A for Treating Allodynic Pain in SCI and MS [Phase 2]
Phase 2 trial investigating botulinum toxin type A for allodynic pain in spinal cord injury and multiple sclerosis; the study status is term…
-
FDA approval · 2015-09-28FDA Approved: TIZANIDINE — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application for tizanidine submitted by Apotex Corp.
-
FDA approval · 2015-09-25FDA Approved: BETASERON — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved a supplemental application for BETASERON (interferon beta-1b) to update the product labeling.
-
CLINICAL_TRIALS trial_result · 2015-09-25Clinical Trial Update: Cognitive-behavior Therapy for MS-Related Chronic Pain [NA]
The trial update reports results from a completed study evaluating cognitive-behavior therapy for chronic pain in people with multiple scler…
-
CLINICAL_TRIALS trial_result · 2015-09-22Clinical Trial Update: Exercises for Urinary Incontinence(UI) of Women With Multiple Sclerosis (MS) [NA]
This is an update on a completed clinical trial evaluating exercises to manage urinary incontinence in women with multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2015-09-09Clinical Trial Update: Neuroprotection With Phenytoin in Optic Neuritis [Phase 2]
Phase 2 trial assessing phenytoin for neuroprotection in optic neuritis (with participants also having multiple sclerosis) has completed.
-
CLINICAL_TRIALS trial_result · 2015-09-07Clinical Trial Update: Single-Dose Study of a New Formulation of BIIB061 [Phase 1]
Phase 1 single-dose study of a new formulation of BIIB061 conducted in multiple sclerosis has completed.
-
CLINICAL_TRIALS withdrawal · 2015-09-07Clinical Trial Update: Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate [Phase 4]
A Phase 4 clinical trial evaluating fatigue in people with relapsing-remitting multiple sclerosis treated with dimethyl fumarate has been wi…
-
CLINICAL_TRIALS trial_result · 2015-09-02Clinical Trial Update: Does Fampridine SR Improve Cognitive Fatigue in Multiple Sclerosis Patients? [Phase 2, Phase 3]
This update reports on Phase 2 and Phase 3 trials evaluating whether sustained-release fampridine (dalfampridine) improves cognitive fatigue…
-
CLINICAL_TRIALS trial_result · 2015-08-27Clinical Trial Update: A Study to Evaluate Safety and Efficacy of DC-TAB in Multiple Sclerosis [Phase 2]
This clinical trial update reports the completion of a Phase 2 study evaluating DC-TAB for safety and efficacy in Multiple Sclerosis.
-
CLINICAL_TRIALS research · 2015-08-26Clinical Trial Update: Fall Risk Reduction in Multiple Sclerosis (FIRMS) [NA]
This document provides an update on the FIRMS clinical trial assessing fall risk reduction in individuals with multiple sclerosis. The curre…
-
CLINICAL_TRIALS trial_result · 2015-08-21Clinical Trial Update: Robot-assisted Gait Training in Patients With Multiple Sclerosis: Efficacy and Comparison With Traditional Methods [NA]
This clinical trial evaluates robot-assisted gait training for people with multiple sclerosis and compares its efficacy to traditional gait …
-
CLINICAL_TRIALS research · 2015-08-20Clinical Trial Update: Safety and Efficacy of an Immunoablative Nonmyeloablative Conditioning Protocol for Autologous Bone Marrow Transplantation (BMT) in Patients With Multiple Sclerosis (MS) [NA]
A clinical trial update describes a conditioning protocol for autologous bone marrow transplantation in multiple sclerosis, evaluating safet…
-
CLINICAL_TRIALS trial_result · 2015-08-11Clinical Trial Update: Placebo vs. Linoleic Acid Controlled Assessment of Treatment Efficacy in MS [Phase 1]
A Phase 1 trial comparing placebo to linoleic acid for treating multiple sclerosis was terminated.
-
CLINICAL_TRIALS research · 2015-08-10Clinical Trial Update: Influence of Emotional Disorders and Executive on the Components Retrograde and Anterograde Episodic Memory in MS [NA]
A clinical trial from University Hospital Caen investigates how emotional disorders and executive function influence retrograde and anterogr…
-
CLINICAL_TRIALS trial_result · 2015-08-07Clinical Trial Update: Autologous Mesenchymal Stem Cells From Adipose Tissue in Patients With Secondary Progressive Multiple Sclerosis [Phase 1, Phase 2]
This clinical trial update reports results from a Phase 1/2 study evaluating autologous adipose-derived mesenchymal stem cells in patients w…
-
FDA approval · 2015-08-04FDA Approved: GILENYA — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for GILENYA (fingolimod HCl) submitted by Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS research · 2015-08-04Clinical Trial Update: Use of an Electronic Diary by People With Multiple Sclerosis [NA]
This document provides an update on a clinical trial examining the use of an electronic diary by people with multiple sclerosis.
-
FDA approval · 2015-08-03FDA Approved: COPAXONE — Supplemental Application (Teva Neuroscience, Inc.)
FDA approved a supplemental application for COPAXONE (glatiramer acetate) from Teva Neuroscience, Inc., resulting in an updated label/indica…